Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity

James Harper, Shannon Burke, Jon Travers, Nicola Rath, Andrew Leinster, Christel Navarro, Ruth Franks, Rebecca Leyland, Kathy Mulgrew, Kelly McGlinchey, Lee Brown, Simon J. Dovedi, Jens-Oliver Koopmann, Nicholas M. Durham, Xing Cheng, Hong Jin, Jim Eyles, Robert W. Wilkinson, Danielle Carroll

Mol Cancer Ther (2021) 20 (9): 1723–1734.

https://doi.org/10.1158/1535-7163.MCT-20-0902

Published: 01 September 2021

View article titled, Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity

Journal Articles

Abstract C2: Selection for combinational studies through biomarker stratification in colorectal patient-derived explant models.

Denis G. Alferez, Jonathan R. Dry, Sarah V. Holt, Susie L. Weston, Gael McWalter, Garry J. Beran, Mitch Revill, Paul D. Smith, Sylvie Guichard, Stephen R. Wedge, Phillip Hedge, Robert W. Wilkinson

Mol Cancer Ther (2011) 10 (11_Supplement): C2.

https://doi.org/10.1158/1535-7163.TARG-11-C2

Published: 12 November 2011

View article titled, Abstract C2: Selection for combinational studies through biomarker stratification in colorectal patient-derived explant models.

Journal Articles

Abstract A13: Characterization of CRC primary explant models in comparison to standard human tumor cell-line-derived CRC xenografts.

Denis G. Alferez, Helen Brown, Jonathan R. Dry, Sarah Runswick, Neil James, Gael McWalter, Jessica Whiteley, Mitch Revill, Garry Beran, Matthew Farren, Neil R. Smith, Phillip Hedge, Simon Barry, Stephen R. Wedge, Robert W. Wilkinson

Mol Cancer Ther (2011) 10 (11_Supplement): A13.

https://doi.org/10.1158/1535-7163.TARG-11-A13

Published: 12 November 2011

View article titled, Abstract A13: Characterization of CRC primary explant models in comparison to standard human tumor cell-line-derived CRC xenografts.

Journal Articles

AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts

Kate F. Byth, Andrew Thomas, Gareth Hughes, Cheryl Forder, Alexandra McGregor, Catherine Geh, Sandra Oakes, Clive Green, Mike Walker, Nicholas Newcombe, Stephen Green, Jim Growcott, Andy Barker, Robert W. Wilkinson

Mol Cancer Ther (2009) 8 (7): 1856–1866.

https://doi.org/10.1158/1535-7163.MCT-08-0836

Published: 14 July 2009

View article titled, AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts

Includes: Supplementary data

Journal Articles

Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity

Jeffrey Cummings, Cassandra Hodgkinson, Rajesh Odedra, Patrizia Sini, Simon P. Heaton, Kirsten E. Mundt, Tim H. Ward, Robert W. Wilkinson, Jim Growcott, Andrew Hughes, Caroline Dive

Mol Cancer Ther (2008) 7 (3): 455–463.

https://doi.org/10.1158/1535-7163.MCT-07-2136

Published: 17 March 2008

View article titled, Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity

Journal Articles

Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of intestinal adenomas in Apc^Min/+ mice

Denis Alferez, Robert W. Wilkinson, Jim Watkins, Richard Poulsom, Nikki Mandir, Stephen R. Wedge, Ian T. Pyrah, Neil R. Smith, Lynsay Jackson, Anderson J. Ryan, Robert A. Goodlad

Mol Cancer Ther (2008) 7 (3): 590–598.

https://doi.org/10.1158/1535-7163.MCT-07-0433

Published: 17 March 2008

View article titled, Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of intestinal adenomas in <em>Apc</em><sup>Min/+</sup> mice

NARROW

Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity

Abstract C2: Selection for combinational studies through biomarker stratification in colorectal patient-derived explant models.

Abstract A13: Characterization of CRC primary explant models in comparison to standard human tumor cell-line-derived CRC xenografts.

AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts

Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity

Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of intestinal adenomas in Apc^Min/+ mice

Email alerts

AACR Journals

Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity

Abstract C2: Selection for combinational studies through biomarker stratification in colorectal patient-derived explant models.

Abstract A13: Characterization of CRC primary explant models in comparison to standard human tumor cell-line-derived CRC xenografts.

AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts

Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity

Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of intestinal adenomas in ApcMin/+ mice

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only

Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of intestinal adenomas in Apc^Min/+ mice